These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38273214)

  • 1. Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
    Wimmer K; Hlauschek D; Balic M; Pfeiler G; Greil R; Singer CF; Halper S; Steger G; Suppan C; Gampenrieder SP; Helfgott R; Egle D; Filipits M; Jakesz R; Sölkner L; Fesl C; Gnant M; Fitzal F
    Breast Cancer Res Treat; 2024 Jun; 205(2):227-239. PubMed ID: 38273214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction.
    Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X
    Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
    Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
    Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the ability of the Clinical Treatment Score at 5 years (CTS5) compared to other risk stratification methods to predict the response to an extended endocrine therapy in breast cancer patients.
    Villasco A; Accomasso F; D'Alonzo M; Agnelli F; Sismondi P; Biglia N
    Breast Cancer; 2021 Sep; 28(5):1131-1140. PubMed ID: 33939116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
    Noordhoek I; Blok EJ; Meershoek-Klein Kranenbarg E; Putter H; Duijm-de Carpentier M; Rutgers EJT; Seynaeve C; Bartlett JMS; Vannetzel JM; Rea DW; Hasenburg A; Paridaens R; Markopoulos CJ; Hozumi Y; Portielje JEA; Kroep JR; van de Velde CJH; Liefers GJ
    J Clin Oncol; 2020 Oct; 38(28):3273-3281. PubMed ID: 32706636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of CTS5 on a Retrospective Cohort of Real-Life Pre- and Postmenopausal Patients Diagnosed With Estrogen Receptor-Positive Breast Cancers: Is It Prognostic?
    Villasco A; Agnelli F; D'Alonzo M; Accomasso F; Sismondi P; Biglia N
    Clin Breast Cancer; 2021 Feb; 21(1):e53-e62. PubMed ID: 32703705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.
    Dowsett M; Sestak I; Regan MM; Dodson A; Viale G; Thürlimann B; Colleoni M; Cuzick J
    J Clin Oncol; 2018 Jul; 36(19):1941-1948. PubMed ID: 29676944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical validity of clinical treatment score 5 (CTS5) for estimating risk of late recurrence in unselected, non-trial patients with early oestrogen receptor-positive breast cancer.
    Richman J; Ring A; Dowsett M; Sestak I
    Breast Cancer Res Treat; 2021 Feb; 186(1):115-123. PubMed ID: 33222093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Treatment Score post-5 years as a predictor of late distant recurrence in hormone receptor-positive breast cancer: systematic review and meta-analysis.
    Shrestha A; Cullinane C; Evoy D; Geraghty J; Rothwell J; Walshe J; McCartan D; McDermott E; Prichard R
    Br J Surg; 2022 Apr; 109(5):411-417. PubMed ID: 35194632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Treatment Score Post-5 Years as a Tool for Risk Estimation of Late Recurrence in Thai Patients With Estrogen-Receptor-Positive, Early Breast Cancer: A Validation Study.
    Dejthevaporn T; Patanayindee P
    Breast Cancer (Auckl); 2023; 17():11782234231186869. PubMed ID: 37533837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen-To Offer More? (aTTom) trial.
    Bartlett JMS; Sgroi DC; Treuner K; Zhang Y; Ahmed I; Piper T; Salunga R; Brachtel EF; Pirrie SJ; Schnabel CA; Rea DW
    Ann Oncol; 2019 Nov; 30(11):1776-1783. PubMed ID: 31504126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index.
    Lee J; Cha C; Ahn SG; Kim D; Park S; Bae SJ; Kim J; Park HS; Park S; Kim SI; Park BW; Jeong J
    Sci Rep; 2020 Oct; 10(1):16850. PubMed ID: 33033359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction.
    Wang C; Xu Y; Lin Y; Zhou Y; Mao F; Zhang X; Shen S; Zhang Y; Sun Q
    Breast; 2022 Jun; 63():61-70. PubMed ID: 35334240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
    Sgroi DC; Sestak I; Cuzick J; Zhang Y; Schnabel CA; Schroeder B; Erlander MG; Dunbier A; Sidhu K; Lopez-Knowles E; Goss PE; Dowsett M
    Lancet Oncol; 2013 Oct; 14(11):1067-1076. PubMed ID: 24035531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.
    Gnant M; Sestak I; Filipits M; Dowsett M; Balic M; Lopez-Knowles E; Greil R; Dubsky P; Stoeger H; Rudas M; Jakesz R; Ferree S; Cowens JW; Nielsen T; Schaper C; Fesl C; Cuzick J
    Ann Oncol; 2015 Aug; 26(8):1685-91. PubMed ID: 25935792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
    Sestak I; Martín M; Dubsky P; Kronenwett R; Rojo F; Cuzick J; Filipits M; Ruiz A; Gradishar W; Soliman H; Schwartzberg L; Buus R; Hlauschek D; Rodríguez-Lescure A; Gnant M
    Breast Cancer Res Treat; 2019 Jul; 176(2):377-386. PubMed ID: 31041683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR
    Noordhoek I; Treuner K; Putter H; Zhang Y; Wong J; Meershoek-Klein Kranenbarg E; Duijm-de Carpentier M; van de Velde CJH; Schnabel CA; Liefers GJ
    Clin Cancer Res; 2021 Jan; 27(1):311-319. PubMed ID: 33109739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer.
    Sanft T; Aktas B; Schroeder B; Bossuyt V; DiGiovanna M; Abu-Khalaf M; Chung G; Silber A; Hofstatter E; Mougalian S; Epstein L; Hatzis C; Schnabel C; Pusztai L
    Breast Cancer Res Treat; 2015 Dec; 154(3):533-41. PubMed ID: 26578401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Distant Recurrence Using EndoPredict Among Women with ER
    Filipits M; Dubsky P; Rudas M; Greil R; Balic M; Bago-Horvath Z; Singer CF; Hlauschek D; Brown K; Bernhisel R; Kronenwett R; Lancaster JM; Fitzal F; Gnant M
    Clin Cancer Res; 2019 Jul; 25(13):3865-3872. PubMed ID: 31064782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.
    Gnant M; Filipits M; Greil R; Stoeger H; Rudas M; Bago-Horvath Z; Mlineritsch B; Kwasny W; Knauer M; Singer C; Jakesz R; Dubsky P; Fitzal F; Bartsch R; Steger G; Balic M; Ressler S; Cowens JW; Storhoff J; Ferree S; Schaper C; Liu S; Fesl C; Nielsen TO;
    Ann Oncol; 2014 Feb; 25(2):339-45. PubMed ID: 24347518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.